
For patients and families in the Western Balkans
Just diagnosed with lung cancer?
You don’t have to understand everything today. Here you’ll find calm, clear information about lung cancer, both non-small cell and small cell, in your language and with help in your country.
- In your language
- A source for every fact
- No sign-up, no cookies
My path
What lies ahead for me?
Three questions, and you see your path: tests, treatments, your questions for the appointment.
Nothing is stored or sent.
1Which type of lung cancer is it?
What happens next
The path after diagnosis
This is how it usually goes.
- ScansA CT or PET-CT shows where something looks unusual.
- BiopsyA small tissue sample is taken.
- PathologyType and stage are determined.
- Biomarker testThe tumour is tested for gene changes and PD-L1.
- Tumour boardSpecialists discuss your case together.
- TreatmentTreatment starts, with regular check-ups.
Living with it
It all revolves around you
Besides treatment, many parts of your life matter. For each one you will find calm, practical advice.
Go to Living with itTopics
Questions many people ask
What do I have?Lung cancer, NSCLC and your report in plain words.Which tests matter?Biomarkers, NGS, biopsy, and how to read your report.What does my test result mean?EGFR, KRAS G12C, PD-L1 and more: what the results mean.What treatments exist?From surgery to targeted therapy.Where can I get treated?Hospitals and cancer centres in your country, and second opinions.What will it cost?What we know about coverage, and what to ask.Am I alone?Patient organisations in the region.How do I live with it?Daily life, feelings, side effects, family.What is research doing?What clinical studies are and how taking part works.Treatment abroad?Travel, visas, insurance and your rights.Quick answersThe most common questions at a glance.
Treatment
How treatment is organised
In advanced NSCLC, treatments follow one another in lines. Clinical trials and supporting treatments can be added at any time.
- First lineThe first treatment
- Targeted tabletWhen the test finds a matching change, for example EGFR, ALK or ROS1.
- Immunotherapy aloneWithout such a change, when PD-L1 is high (50% or more).e.g. pembrolizumab, cemiplimab, atezolizumab
- Immunotherapy with chemotherapyWithout such a change, at any PD-L1 level. This also applies with KRAS G12C.e.g. platinum chemotherapy with pembrolizumab
- Second lineIf the cancer grows again
- Targeted tablet used only nowFor some changes it is authorised in the EU only after a first treatment, above all KRAS G12C.for KRAS G12C: sotorasib or adagrasib
- Next targeted treatmentWhen the first tablet stops working. A new test sometimes shows what has changed.
- ChemotherapyWhen no targeted treatment fits. After immunotherapy alone, often with platinum.e.g. docetaxel
- Third lineFurther options
- What has not been given yetFor example a targeted tablet after chemotherapy, or the other way round.
- Clinical trialNew medicines and combinations are being tested, including newer KRAS inhibitors.
- Focus on comfortWhen further medicines would burden more than help. You decide this together with your team.
Alongside, when it helps
- RadiotherapyAimed at single spots, or to ease symptoms.
- SurgeryMainly in early stages, when the tumour can be removed completely.
- Supportive careFor pain, breathlessness and nausea. Always, from the start.
Updates
What changed recently
- Federation of BiH: pembrolizumab and atezolizumab now explicitly for lung cancerWith its decision of 23 September 2026 (Official Gazette of the Federation 76/26), the government changed the entries for pembrolizumab and atezolizumab on the Solidarity Fund list. We checked what this means for lung cancer.
- Serbia: what the RFZO lists from 11 July 2026 pay for in lung cancerLists B and C of the RFZO health insurance fund apply in the version from 11 July 2026. We checked which lung cancer medicines they include, and on what conditions.
- Montenegro: what the October 2026 FZOCG medicines list pays for in lung cancerThe medicines list of the FZOCG health insurance fund is available in its October 2026 version. We checked which lung cancer medicines it includes and who proposes the treatment.